Literature DB >> 21643784

Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD.

Maher R Khdour1, Ashley M Agus, Joseph C Kidney, Bronagh M Smyth, James C McElnay, James C Elnay, Grainne E Crealey.   

Abstract

OBJECTIVE: To undertake a cost-utility analysis (CUA) of a pharmacy-led self-management programme for Chronic Obstructive Pulmonary Disease (COPD).
SETTING: A single outpatient COPD clinic at the Mater Hospital, Belfast, Northern Ireland between.
METHOD: CUA alongside a randomised control trial. The economic analysis used data from 127 COPD patients aged over 45 years, with an FEV1 of 30-80% of the predicted normal value. Participants received either a pharmacy-led education and self-management programme, or usual care. One year costs were estimated from the perspective of the National Health Service and Personal Social Services and quality-adjusted life years (QALYs) were calculated based on responses to the EQ-5D at baseline, 6 and 12 months. MAIN OUTCOME MEASURE: Cost per QALY gained.
RESULTS: The mean differences in costs and effects between the self-management and education programme and usual care were -£671.59 (95 CI%: -£1,584.73 to -£68.14) and 0.065 (95% CI; 0.000-0.128). Thus the intervention was the dominant strategy as it was both less costly and more effective than usual care. The probability of the intervention being cost-effective was 95% at a threshold of £20,000/QALY gained. Sensitivity analyses indicated that conclusions were robust to variations in most of the key parameters.
CONCLUSION: The self-management and education programme was found to be highly cost-effective compared to usual care. Further research is required to establish what aspects of self-management and education programmes have the greatest impact on cost-effectiveness.

Entities:  

Mesh:

Year:  2011        PMID: 21643784     DOI: 10.1007/s11096-011-9524-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  27 in total

1.  The economic burden of COPD.

Authors:  S D Sullivan; S D Ramsey; T A Lee
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

2.  Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility.

Authors:  Andrea Manca; Neil Hawkins; Mark J Sculpher
Journal:  Health Econ       Date:  2005-05       Impact factor: 3.046

3.  Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey.

Authors:  S Rennard; M Decramer; P M A Calverley; N B Pride; J B Soriano; P A Vermeire; J Vestbo
Journal:  Eur Respir J       Date:  2002-10       Impact factor: 16.671

4.  Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease.

Authors:  E Monninkhof; P van der Valk; T Schermer; J van der Palen; C van Herwaarden; G Zielhuis
Journal:  Chron Respir Dis       Date:  2004       Impact factor: 2.444

5.  Pharmacoeconomic evaluation of COPD.

Authors:  D E Hilleman; N Dewan; M Malesker; M Friedman
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

6.  Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.

Authors:  A Robinson; D G Thompson; D Wilkin; C Roberts
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  The burden of COPD in the U.K.: results from the Confronting COPD survey.

Authors:  M Britton
Journal:  Respir Med       Date:  2003-03       Impact factor: 3.415

8.  Economic benefits of teaching patients with chronic obstructive pulmonary disease about their illness. The PASTMA Group.

Authors:  L Tougaard; T Krone; A Sorknaes; H Ellegaard
Journal:  Lancet       Date:  1992-06-20       Impact factor: 79.321

Review 9.  Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature.

Authors:  Talia S Foster; Jeffrey D Miller; Jeno P Marton; John P Caloyeras; Mason W Russell; Joseph Menzin
Journal:  COPD       Date:  2006-12       Impact factor: 2.409

10.  Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care.

Authors: 
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

View more
  13 in total

Review 1.  Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations.

Authors:  Edwin J M Oberjé; Reina J A de Kinderen; Silvia M A A Evers; Cees M J van Woerkum; Marijn de Bruin
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

Review 2.  Evaluation of pharmacist care for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Han Zhong; Xiao-Jun Ni; Min Cui; Xiao-Yan Liu
Journal:  Int J Clin Pharm       Date:  2014-10-22

Review 3.  Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.

Authors:  Maxwell Howcroft; E Haydn Walters; Richard Wood-Baker; Julia Ae Walters
Journal:  Cochrane Database Syst Rev       Date:  2016-12-19

Review 4.  Integrated disease management interventions for patients with chronic obstructive pulmonary disease.

Authors:  Charlotte C Poot; Eline Meijer; Annemarije L Kruis; Nynke Smidt; Niels H Chavannes; Persijn J Honkoop
Journal:  Cochrane Database Syst Rev       Date:  2021-09-08

5.  Impact of Pharmacist-Led Clinics on Health Outcomes of Patients With Diabetes at a Ministry of Health Diabetes & Endocrinology Center, Saudi Arabia: A Retrospective Study.

Authors:  Saleh F Alqifari; Bader AlMharwal; Rahaf Aldawish; Salman A Almokhlef
Journal:  Cureus       Date:  2022-06-14

Review 6.  Self-management interventions for people with chronic obstructive pulmonary disease.

Authors:  Jade Schrijver; Anke Lenferink; Marjolein Brusse-Keizer; Marlies Zwerink; Paul Dlpm van der Valk; Job van der Palen; Tanja W Effing
Journal:  Cochrane Database Syst Rev       Date:  2022-01-10

7.  Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.

Authors:  Job Fm van Boven; Eline Tommelein; Koen Boussery; Els Mehuys; Stefan Vegter; Guy Go Brusselle; Maureen Pmh Rutten-van Mölken; Maarten J Postma
Journal:  Respir Res       Date:  2014-06-14

8.  Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model.

Authors:  Ingrid E H Kremer; Mickael Hiligsmann; Josh Carlson; Marita Zimmermann; Peter J Jongen; Silvia M A A Evers; Svenja Petersohn; Xavier G L V Pouwels; Nick Bansback
Journal:  Med Decis Making       Date:  2020-11       Impact factor: 2.583

9.  Effect of continuous nursing care based on the IKAP theory on the quality of life of patients with chronic obstructive pulmonary disease: A randomized controlled study.

Authors:  Xin-Xia Li; Xue-Wei Du; Wen Song; Chang Lu; Wen-Nv Hao
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

Review 10.  Can self-management programmes change healthcare utilisation in COPD?: A systematic review and framework analysis.

Authors:  Katelyn R Smalley; Lisa Aufegger; Kelsey Flott; Erik K Mayer; Ara Darzi
Journal:  Patient Educ Couns       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.